11 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European Prevention of Alzheimer’s Dementia Consortium (EPAD)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet
40
Participants partenaires
TERMINÉ
European Lead Factory (EUC²LID)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet
34
Participants partenaires
TERMINÉ
Oral biopharmaceutics tools (ORBITO)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Voir le projet
28
Participants partenaires
TERMINÉ
Delivering European Translational Information & Knowledge Management Services (ETRIKS)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Voir le projet
17
Participants partenaires
TERMINÉ
Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet
30
Participants partenaires
TERMINÉ
European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)
Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet
34
Participants partenaires
TERMINÉ
The Open Pharmacological Concepts Triple Store (OPEN PHACTS)
Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,
Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Voir le projet
32
Participants partenaires
TERMINÉ
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet
38
Participants partenaires
TERMINÉ
Novel Statistical Methodology for Diagnostic/Prognostic and Therapeutic Studies and Systematic Reviews (MEDIASRES)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
"Novel statistical methodology promises to greatly facilitate development of approaches for personalised medicine. While state-of-the-art statistical techniques have already advanced clinical trials and diagnostic/prognostic studies as the major source of evidence in clinical medicine, increasing availability of molecular techniques holds an even greater promise. However, for leveraging such infor ...
Voir le projet
10
Participants partenaires
TERMINÉ
Understanding chronic pain and improving its treatment (EUROPAIN)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,
We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Re ...
Voir le projet
29
Participants partenaires
TERMINÉ
Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)
Date du début: 1 sept. 2009, Date de fin: 28 févr. 2015,
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Voir le projet